世界中医药
世界中醫藥
세계중의약
World Chinese Medicine
2015年
9期
1344-1346
,共3页
通心络%阿托伐他汀%冠心病%血脂
通心絡%阿託伐他汀%冠心病%血脂
통심락%아탁벌타정%관심병%혈지
TXL%Atorvastatin%Coronary heart disease%Blood lipids
目的：探讨通心络胶囊联合阿托伐他汀对冠心病患者血脂的影响。方法：选取我院68例冠心病患者，将其随机分为对照组和观察组，每组各34例。对照组患者采用常规治疗，观察组患者在常规治疗的基础上加用通心络胶囊联合阿托伐他汀治疗。比较2组患者治疗前后的血脂水平、血脂达标率及不良反应发生率。结果：2组患者治疗前 TC、TG、LDL-C、HDL-C 等血脂指标水平差异均无统计学意义（P ＞0．05）；治疗3个月后2组患者 TC、TG、LDL-C 水平均低于治疗前，HDL-C 水平均高于治疗前，且观察组优于对照组，差异均具有统计学意义（P ＜0．05）。治疗后观察组 TC、TG、LDL-C 达标率均显著高于对照组，组间差异均有统计学意义（P ＜0．05）。2组患者均未出现严重肝肾不良反应，其不良反应发生率比较差异无统计学意义（P ＞0．05）。结论：通心络胶囊联合阿托伐他汀对冠心病，可显著降低血清 TC、TG、LDL-C 水平，提高血脂达标率，且具有较高的临床安全性，值得应用推广于临床。
目的：探討通心絡膠囊聯閤阿託伐他汀對冠心病患者血脂的影響。方法：選取我院68例冠心病患者，將其隨機分為對照組和觀察組，每組各34例。對照組患者採用常規治療，觀察組患者在常規治療的基礎上加用通心絡膠囊聯閤阿託伐他汀治療。比較2組患者治療前後的血脂水平、血脂達標率及不良反應髮生率。結果：2組患者治療前 TC、TG、LDL-C、HDL-C 等血脂指標水平差異均無統計學意義（P ＞0．05）；治療3箇月後2組患者 TC、TG、LDL-C 水平均低于治療前，HDL-C 水平均高于治療前，且觀察組優于對照組，差異均具有統計學意義（P ＜0．05）。治療後觀察組 TC、TG、LDL-C 達標率均顯著高于對照組，組間差異均有統計學意義（P ＜0．05）。2組患者均未齣現嚴重肝腎不良反應，其不良反應髮生率比較差異無統計學意義（P ＞0．05）。結論：通心絡膠囊聯閤阿託伐他汀對冠心病，可顯著降低血清 TC、TG、LDL-C 水平，提高血脂達標率，且具有較高的臨床安全性，值得應用推廣于臨床。
목적：탐토통심락효낭연합아탁벌타정대관심병환자혈지적영향。방법：선취아원68례관심병환자，장기수궤분위대조조화관찰조，매조각34례。대조조환자채용상규치료，관찰조환자재상규치료적기출상가용통심락효낭연합아탁벌타정치료。비교2조환자치료전후적혈지수평、혈지체표솔급불량반응발생솔。결과：2조환자치료전 TC、TG、LDL-C、HDL-C 등혈지지표수평차이균무통계학의의（P ＞0．05）；치료3개월후2조환자 TC、TG、LDL-C 수평균저우치료전，HDL-C 수평균고우치료전，차관찰조우우대조조，차이균구유통계학의의（P ＜0．05）。치료후관찰조 TC、TG、LDL-C 체표솔균현저고우대조조，조간차이균유통계학의의（P ＜0．05）。2조환자균미출현엄중간신불량반응，기불량반응발생솔비교차이무통계학의의（P ＞0．05）。결론：통심락효낭연합아탁벌타정대관심병，가현저강저혈청 TC、TG、LDL-C 수평，제고혈지체표솔，차구유교고적림상안전성，치득응용추엄우림상。
Objective:To investigate the effect of Tongxinluo with atorvastatin on blood lipids in patients with coronary heart dis-ease.Methods:68 cases with coronary heart disease were selected and randomly divided into control group and observation group, 40 cases in each group.The patients in control group received conventional treatment,while patients in observation group added Tongxinluo and atorvastatin treatment.Lipid levels,lipid compliance rate and incidence of adverse reactions were compared before and after treatment.Results:The levels of serum lipids TC,TG,LDL-C,HDL-C,etc in two groups of patients before treatment were not statistically significant (P >0.05).3 months after treatment,both groups TC,TG,LDL-C levels were lower than before treatment,HDL-C levels were higher than before treatment,and the degree of improvement of observation group was better than that in the control group,the differences were statistically significant (P <0.05).After treatment,the compliance rates of TC, TG,LDL-C in observation group was significantly higher than that in the control group (P <0.05).There were no serious adverse reactions on liver and kidney in the two groups,the incidence of adverse reactions was not significantly different between the two groups (P >0.05).Conclusion:In treating coronary heart disease,Tongxinluo capsule combined with atorvastatincan signifi-cantly reduce the levels of serum TC,TG,LDL-C,improve blood lipids compliance rate,and has a high clinical safety.It is wor-thy of clinical application and promotion.
